These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 39118220)

  • 21. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
    Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G
    World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.
    Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A
    Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.
    Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL
    Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Hermanowicz N
    CNS Spectr; 2018 Dec; 23(6):352-354. PubMed ID: 30588904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 31. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
    Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F
    Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
    Daeschler D; Fugh-Berman A
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease psychosis associated with accelerated multidomain cognitive decline.
    Pisani S; Gosse L; Aarsland D; Ray Chaudhuri K; Ballard C; Ffytche D; Velayudhan L; Bhattacharyya S
    BMJ Ment Health; 2024 Jul; 27(1):1-10. PubMed ID: 39043465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms.
    Zhang S; Ma Y
    World J Psychiatry; 2022 Sep; 12(9):1127-1140. PubMed ID: 36186499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Characteristics of Minor Hallucinations in Chinese Parkinson's Disease Patients.
    Zhang Y; Zhang GY; Zhu XB; Zhang ZE; Gan J; Liu ZG
    Front Aging Neurosci; 2021; 13():723405. PubMed ID: 35126085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.